Immix Biopharma Inc. (IMMX)

AI Score

Unlock

1.74

-0.01 (-0.57%)

At close: Apr 25, 2025, 10:53 AM

Immix Biopharma Balance Sheet Statement

Financials in USD. Fiscal year is January - December.

Fiscal Year	Q4 2024	Q3 2024	Q2 2024	Q1 2024	Q4 2023	Q3 2023	Q2 2023	Q1 2023	Q4 2022	Q3 2022	Q2 2022	Q1 2022	Q4 2021	Q3 2021	Q2 2021	Q1 2021	Q4 2020	Q1 2020
Period Ending	Dec 31, 2024	Sep 30, 2024	Jun 30, 2024	Mar 31, 2024	Dec 31, 2023	Sep 30, 2023	Jun 30, 2023	Mar 31, 2023	Dec 31, 2022	Sep 30, 2022	Jun 30, 2022	Mar 31, 2022	Dec 31, 2021	Sep 30, 2021	Jun 30, 2021	Mar 31, 2021	Dec 31, 2020	Mar 31, 2020
Cash & Equivalents	17.68M	19.69M	23.98M	29.32M	17.51M	19.58M	12.65M	11.46M	13.44M	16.92M	18.4M	19.06M	17.64M	37.99K	110.6K	-391.09K	391.09K	-734.01K
Short-Term Investments	n/a	n/a	n/a	n/a	n/a	n/a	n/a	n/a	n/a	n/a	n/a	n/a	n/a	n/a	n/a	782.17K	n/a	1.47M
Long-Term Investments	n/a	n/a	n/a	n/a	n/a	n/a	n/a	n/a	n/a	n/a	n/a	n/a	n/a	n/a	n/a	n/a	n/a	n/a
Other Long-Term Assets	20.42K	20.42K	20.42K	20.42K	87.23K	103.19K	56.72K	175.13K	6.72K	0.00	n/a	n/a	n/a	246.02K	52.67K	-391.09K	n/a	-734.01K
Receivables	1.97M	1.98M	1.98M	n/a	1.17M	652.48K	297K	322.38K	255.71K	182.34K	165.05K	63.73K	25.72K	188.63K	n/a	n/a	n/a	n/a
Inventory	n/a	n/a	n/a	1.00	n/a	n/a	n/a	n/a	n/a	n/a	n/a	n/a	-25.72K	n/a	n/a	n/a	n/a	n/a
Other Current Assets	32.27K	36.52K	105.78K	2.2M	44.58K	167K	2.56M	1.25M	78.07K	n/a	n/a	n/a	n/a	n/a	n/a	n/a	n/a	n/a
Total Current Assets	20.2M	22.76M	27.33M	32.92M	19.79M	22.33M	15.51M	13.03M	14.9M	17.39M	19.08M	20.01M	18.19M	242.92K	291.97K	391.09K	532.24K	734.01K
Property-Plant & Equipment	2.73M	2.37M	1.48M	1.41M	50.18K	40.08K	2.55K	3.06K	3.56K	4.13K	4.69K	5.08K	5.7K	6.32K	6.93K	n/a	7.36K	n/a
Goodwill & Intangibles	n/a	n/a	n/a	n/a	n/a	n/a	n/a	n/a	n/a	n/a	n/a	n/a	n/a	n/a	n/a	n/a	n/a	n/a
Total Long-Term Assets	2.75M	2.39M	1.51M	1.43M	137.41K	143.27K	59.27K	178.19K	10.28K	4.13K	4.69K	5.08K	5.7K	252.34K	59.61K	-391.09K	7.36K	-734.01K
Total Assets	22.95M	25.14M	28.84M	34.35M	19.93M	22.47M	15.57M	13.21M	14.91M	17.4M	19.09M	20.02M	18.19M	495.26K	351.58K	n/a	539.6K	n/a
Account Payables	5.39M	3.29M	2.35M	3.51M	1.43M	1.57M	2.4M	1.47M	143.07K	646.46K	977.21K	305.68K	142.94K	618.03K	182.78K	n/a	252.34K	n/a
Deferred Revenue	n/a	n/a	-48.36K	n/a	n/a	n/a	n/a	n/a	n/a	n/a	n/a	n/a	-192.94K	435.99K	402.77K	n/a	342.84K	n/a
Short-Term Debt	n/a	n/a	48.36K	n/a	n/a	n/a	n/a	n/a	n/a	n/a	n/a	50K	50K	4.1M	4.1M	n/a	4.1M	n/a
Other Current Liabilities	658.16K	198.09K	1.29M	n/a	n/a	1.13M	n/a	n/a	n/a	n/a	n/a	n/a	n/a	1.31M	1.31M	n/a	575K	n/a
Total Current Liabilities	8.69M	6.56M	3.9M	5.66M	3.72M	2.83M	2.4M	1.47M	1.27M	646.46K	977.21K	365.09K	202.04K	6.46M	6M	n/a	5.27M	n/a
Long-Term Debt	n/a	n/a	n/a	n/a	n/a	n/a	n/a	n/a	n/a	n/a	n/a	n/a	n/a	146.94K	126.81K	n/a	n/a	n/a
Other Long-Term Liabilities	n/a	n/a	n/a	n/a	n/a	n/a	n/a	n/a	475K	n/a	n/a	n/a	n/a	80K	80K	n/a	n/a	n/a
Total Long-Term Liabilities	1.01M	1.03M	1.04M	1.06M	n/a	n/a	n/a	n/a	475K	646.46K	n/a	355.68K	n/a	226.94K	206.81K	n/a	n/a	n/a
Total Liabilities	9.7M	7.59M	4.94M	6.72M	3.72M	2.83M	2.4M	1.47M	1.75M	646.46K	977.21K	365.09K	202.04K	6.69M	6.2M	n/a	5.27M	n/a
Total Debt	1.07M	1.09M	1.09M	1.09M	n/a	n/a	n/a	n/a	n/a	n/a	n/a	50K	50K	4.25M	4.23M	n/a	4.1M	n/a
Common Stock	2.76K	2.76K	2.75K	2.65K	2K	1.97K	1.63K	1.4K	1.4K	1.4K	1.4K	1.39K	1.32K	338.00	338.00	n/a	338.00	n/a
Retained Earnings	-75.02M	-70.21M	-63.06M	-58.67M	-53.41M	-48.32M	-44.04M	-40.46M	-37.99M	-34.19M	-32.65M	-31.09M	-29.76M	-7M	-6.6M	n/a	-5.37M	n/a
Comprehensive Income	-1.06K	192.05K	116.97K	89.61K	134.67K	46.73K	80.88K	82.55K	87.02K	62.05K	102.44K	141K	125.41K	123.87K	127.39K	-4.73M	131.86K	-3.65M
Shareholders Equity	13.25M	17.55M	23.89M	27.92M	16.41M	19.77M	13.23M	11.77M	13.16M	16.75M	18.11M	19.65M	17.99M	-6.2M	-5.85M	-4.73M	-4.73M	-3.65M
Total Investments	n/a	n/a	n/a	n/a	n/a	n/a	n/a	n/a	n/a	n/a	n/a	n/a	n/a	n/a	n/a	782.17K	n/a	1.47M